- Home
- NL vs NGNE Comparison
NL vs NGNE Comparison
Compare NL & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- NGNE
- Stock Information
- Founded
- NL 1891
- NGNE 2003
- Country
- NL United States
- NGNE United States
- Employees
- NL N/A
- NGNE N/A
- Industry
- NL Major Chemicals
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- NL Industrials
- NGNE Health Care
- Exchange
- NL Nasdaq
- NGNE Nasdaq
- Market Cap
- NL 320.5M
- NGNE 325.3M
- IPO Year
- NL N/A
- NGNE N/A
- Fundamental
- Price
- NL $6.52
- NGNE $18.48
- Analyst Decision
- NL Sell
- NGNE Strong Buy
- Analyst Count
- NL 1
- NGNE 7
- Target Price
- NL $6.00
- NGNE $41.86
- AVG Volume (30 Days)
- NL 27.5K
- NGNE 110.1K
- Earning Date
- NL 08-06-2025
- NGNE 08-11-2025
- Dividend Yield
- NL 5.50%
- NGNE N/A
- EPS Growth
- NL 141.37
- NGNE N/A
- EPS
- NL 1.10
- NGNE N/A
- Revenue
- NL $152,721,000.00
- NGNE N/A
- Revenue This Year
- NL $15.75
- NGNE N/A
- Revenue Next Year
- NL $2.44
- NGNE N/A
- P/E Ratio
- NL $5.96
- NGNE N/A
- Revenue Growth
- NL N/A
- NGNE N/A
- 52 Week Low
- NL $5.29
- NGNE $6.88
- 52 Week High
- NL $9.42
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- NL 51.90
- NGNE 35.93
- Support Level
- NL $6.30
- NGNE $19.59
- Resistance Level
- NL $6.82
- NGNE $20.46
- Average True Range (ATR)
- NL 0.33
- NGNE 1.23
- MACD
- NL 0.04
- NGNE -0.20
- Stochastic Oscillator
- NL 60.00
- NGNE 13.37
About NL NL Industries Inc.
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.